BEIJING, Oct. 24, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that it has been included in Forbes Magazine's annual list of Asia's "200 Best Under a Billion" for the year 2011. The Company was also named to the same list for the year 2009.
According to Forbes Asia, Forbes considered only listed companies that have been publicly traded for at least a year and have achieved revenues between US$ 5 million and $1 billion.
The 200 Asia-Pacific companies were selected from more than 15,000 companies, based on their earnings growth, sales growth, and shareholders' return on equity in the past 12 months and over the past three years. For the detailed methodology, please visit http://www.forbes.com.
China Biologic was one of the 65 companies in China and Hong Kong to make the prestigious list.
Mr. Chao Ming Zhao, the Company's Chief Executive Officer, said, "We are honored that Forbes Magazine has recognized China Biologic as one of the Asia-Pacific region's best mid-sized companies for a second time. We believe this accolade reflects our outstanding financial performance, as well as our position as one of the leading plasma-based biopharmaceutical companies in China."
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. China Biologic's plasma
|SOURCE China Biologic Products, Inc.|
Copyright©2010 PR Newswire.
All rights reserved